Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Papazol is a fixed-dose combination pharmaceutical product consisting of bendazol (also known as dibazole) and papaverine hydrochloride. It is primarily manufactured and marketed in Russia and other CIS countries as a myotropic antispasmodic and vasodilator. Papaverine, an opium alkaloid derivative, acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cAMP and leading to smooth muscle relaxation. Bendazol is a benzimidazole derivative that exerts direct vasodilatory effects on smooth muscles and possesses mild adaptogenic and immunostimulating properties. The combination is indicated for the symptomatic relief of arterial hypertension, spasms of peripheral arteries, and spasms of smooth muscles in the gastrointestinal tract, such as pylorospasm and colitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on papazol.